Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Themis Medicare Ltd (THEMISMED) is currently trading at 81.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Themis Medicare Limited manufactures finished pharmaceutical formulations and synthetic Active Pharmaceutical Ingredients (APIs), operates a hospital-focused commercial division, and exports to over 44 countries while operating three state-of-the-art manufacturing facilities across India with EU GMP certifications for key units. Q3 FY26 showed a notable profitability turnaround with consolidated revenue of ₹90.13 crore, EBITDA of ₹9.8 crore (10.9% margin) and PAT of ₹10.09 crore, driven by API growth and cost rationalization, despite 9M FY26 revenue falling 20.4% year-on-year to ₹265.7 crore and negative cumulative profitability. The company is strategically pivoting toward a higher-margin Hospital Business, which contributed 49% of revenue in 9M FY26 versus 38% for FY24-25, reflecting an intentional shift in sales mix and dedicated commercial effort to capture fragmented hospital and critical care segments in India. Vertically integrated manufacturing capacity, EU GMP approvals, and consistent R&D investment (historical annual spend ~₹13 crore and management guidance of ~3% of revenue) underpin Themis Medicare’s product pipeline and aim to support in-house API consumption and external commercial sales as part of growth plans.
Over the past 52 weeks, Themis Medicare Ltd has traded between a low of ₹73.79 and a high of ₹179.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Themis Medicare Ltd has a market capitalization of approximately 749.33. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Themis Medicare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -43.18 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 749.33 Cr, Themis Medicare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Themis Medicare Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Themis Medicare Ltd is -43.18. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
3
Neutral
7
Bullish
4
Bearish
27
Neutral
7
Bullish
12
Bearish
24
Neutral
0
Bullish
8
Themis Medicare Limited manufactures finished pharmaceutical formulations and synthetic Active Pharmaceutical Ingredients (APIs), operates a hospital-focused commercial division, and exports to over 44 countries while operating three state-of-the-art manufacturing facilities across India with EU GMP certifications for key units.
Q3 FY26 showed a notable profitability turnaround with consolidated revenue of ₹90.13 crore, EBITDA of ₹9.8 crore (10.9% margin) and PAT of ₹10.09 crore, driven by API growth and cost rationalization, despite 9M FY26 revenue falling 20.4% year-on-year to ₹265.7 crore and negative cumulative profitability.
The company is strategically pivoting toward a higher-margin Hospital Business, which contributed 49% of revenue in 9M FY26 versus 38% for FY24-25, reflecting an intentional shift in sales mix and dedicated commercial effort to capture fragmented hospital and critical care segments in India.
Vertically integrated manufacturing capacity, EU GMP approvals, and consistent R&D investment (historical annual spend ~₹13 crore and management guidance of ~3% of revenue) underpin Themis Medicare’s product pipeline and aim to support in-house API consumption and external commercial sales as part of growth plans.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
749 Cr
High Risk
-43.2
28.9
—
2.2
179.25
73.79
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
313.40 | 992 Cr | 20.30 | 2.04 | 0.32 | 10.52 | 10.52 | 5.94 | |
253.80 | 852 Cr | 21.39 | 11.00 | 0.00 | 51.51 | 27.98 | 10.39 | |
338.45 | 812 Cr | 21.54 | 3.46 | 0.30 | 13.89 | 19.49 | 12.00 | |
81.53 | 749 Cr | -43.18 | 2.16 | 0.61 | -7.10 | -3.47 | -2.99 | |
19.47 | 744 Cr | -9.98 | 1.47 | 0.51 | 12.11 | 12.71 | -8.73 | |
497.65 | 635 Cr | 35.34 | 4.13 | 0.00 | 13.30 | 16.18 | 8.86 | |
126.65 | 611 Cr | 37.03 | 1.22 | 2.37 | 3.51 | 5.38 | 2.04 |
